melatonin has been researched along with cardiovascular agents in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colantuono, G; Di Venosa, N; Fiore, T; Moro, N; Paradies, G; Petrosillo, G; Ruggiero, FM; Tiravanti, E | 1 |
| Laudon, M; Paulis, L; Simko, F | 1 |
| da Costa, CM; do Prado Júnior, JC; dos Santos, CD; Kuehn, CC; Mendonça, VJ; Miranda, MA; Oliveira, LG | 1 |
| Aarøe, J; Ekeloef, S; Fonnes, S; Gasbjerg, LS; Gögenur, I; Halladin, N; Jensen, SE; Jonsson, G; Rosenberg, J; Rosenkilde, MM; Zaremba, T | 1 |
| Song, YJ; Wu, W; Zhong, CB | 1 |
2 review(s) available for melatonin and cardiovascular agents
| Article | Year |
|---|---|
Cardiovascular effects of melatonin receptor agonists.
Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Circadian Rhythm; Drug Design; Humans; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2 | 2012 |
Cardioprotective effects of melatonin: Focusing on its roles against diabetic cardiomyopathy.
Topics: Animals; Cardiovascular Agents; Diabetic Cardiomyopathies; Heart; Humans; Melatonin; Myocardium; Signal Transduction | 2020 |
1 trial(s) available for melatonin and cardiovascular agents
| Article | Year |
|---|---|
Effect of Intracoronary and Intravenous Melatonin on Myocardial Salvage Index in Patients with ST-Elevation Myocardial Infarction: a Randomized Placebo Controlled Trial.
Topics: Aged; Biomarkers; Cardiovascular Agents; Denmark; Double-Blind Method; Female; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Melatonin; Middle Aged; Myocardial Reperfusion Injury; Myocardium; Percutaneous Coronary Intervention; Recovery of Function; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2017 |
2 other study(ies) available for melatonin and cardiovascular agents
| Article | Year |
|---|---|
Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening.
Topics: Animals; Antioxidants; Calcium; Cardiolipins; Cardiovascular Agents; Cyclosporine; Cytochromes c; Heart Rate; In Vitro Techniques; L-Lactate Dehydrogenase; Lipid Peroxidation; Male; Melatonin; Membrane Potential, Mitochondrial; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; NAD; Necrosis; Perfusion; Rats; Rats, Wistar; Recovery of Function; Time Factors; Ventricular Function, Left; Ventricular Pressure | 2009 |
Protective actions of melatonin against heart damage during chronic Chagas disease.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Cardiovascular Agents; Chagas Cardiomyopathy; Cytokines; Male; Melatonin; Myocardium; Nitric Oxide; Rats; Rats, Wistar; Treatment Outcome; Trypanosoma cruzi | 2013 |